• New Tool On Susan G. Komen® Website Helps People Living With Metastatic Breast Cancer Find Clinical Trials


    A new tool on Susan G. Komen’s website, komen.org, aims to make it easier for individuals living with metastatic breast cancer to identify clinical trials that they may be eligible to join. The organization today announced that the Metastatic Trial Search (MTS), a web-based personalized clinical trial matching tool developed by Komen partner BreastCancerTrials.org, is available on its website. The MTS offers women and men with metastatic breast cancer information about their clinical trial options that may help them make treatment decisions and also play a vital role in breast cancer research for future generations.

    “We hope that by adding this innovative tool to our already comprehensive website, more women and men living with metastatic disease can benefit from promising experimental treatments today, while supporting the research that will help patients in the future,” said Victoria Wolodzko, Vice President of Research and Community Health Program Operations.

    “Our focus at Komen is on reducing the current number of U.S. breast cancer deaths by half in the next ten years, and we will only achieve this through significant improvements in our ability to prevent, detect and treat metastatic breast cancer. Clinical trials have already greatly improved breast cancer treatment, but more and better treatment options are needed for those facing metastatic breast cancer today, making this tool essential,” Wolodzko added.

    The MTS is now available to the more than 15,000 individuals who visit komen.org every day seeking safe and accurate information about breast cancer and resources that can help them through their journey.

    Since 2011, Komen has provided $126,000 in funding to support BreastCancerTrials.org and its work to make clinical trials more accessible to all breast cancer patients through its easy-to-understand information and patient-centered trial matching tools.

    "From the beginning, our mission has been to make consideration of clinical trials the norm rather than the exception," said Elly Cohen, Director of BreastCancerTrials.org. "We are enormously grateful for Komen’s early support of BreastCancerTrials.org and for continuing our partnership through Metastatic Trial Search. We look forward to working together to help ensure that metastatic breast cancer patients who might benefit the most from clinical trials have easy access to the most current research."

    MTS was developed by BreastCancerTrials.org and launched in October 2015 in collaboration with five non-profit organizations including the Metastatic Breast Cancer Network, Breastcancer.org, Living Beyond Breast Cancer, Young Survival Coalition and Triple Step Toward the Cure. Funded by the Avon-Pfizer Metastatic Breast Cancer Grants Program with additional support from the Metastatic Breast Cancer Alliance, of which Komen is a founding member, and industry sponsors, MTS is now available on additional member websites.